

Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers

Supplementary Materials

Supplementary Table S1: Clinical characteristics for newly diagnosed AML patients ($n = 67$).

See Supplementary_Table_S1

Supplementary Table S2: Clinical, cytogenetic and molecular genetic characteristics of primary AML samples ($n = 12$) profiled on microarrays to obtain BV6 response associated signature.

See Supplementary_Table_S2

Supplementary Table S3: Top 100 genes differentially expressed in BV6 versus DMSO treated samples, according to Class comparison analysis. See Supplementary_Table_S3

Supplementary Table S4: Differentially regulated Biocarta pathways among BV6- and DMSO-treated primary AML samples, according to LS/KS permutation testing (Pathway comparison).

Light grey script indicated pathways not significant in LS/KS testing, but in GSA test. See Supplementary_Table_S4